Shanghai Escugen Biotechnology Co., Ltd

This study tested a new drug called ESG401 in 156 people with advanced solid tumors (like breast, lung, or colon cancer) that had stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors. The study was completed and measu…

This early-stage study tested a new antibody drug, ESG206, in 13 adults with B-cell blood cancers that had not responded to standard treatments. The main goals were to check safety and find the best dose. Researchers also looked for signs that the drug could shrink tumors.